Valion Bio (VBIO) Current Assets (2021 - 2026)

Valion Bio has reported Current Assets for 6 years, with the latest figure at $3.4 million in Q2 2026.

• On a quarterly basis, Current Assets rose 83.6% year-over-year to $3.4 million in Q2 2026; TTM through Jun 2026 was $3.4 million, a 83.6% increase from a year earlier, with the FY2025 full-year figure at $13.0 million, up 392.84% from the prior year.
• Current Assets was $3.4 million for Q2 2026 at Valion Bio, down from $13.0 million in the prior quarter.
• The five-year high for Current Assets was $13.0 million in Q4 2025, with the low at $1.3 million in Q1 2025.
• Average Current Assets over 5 years is $5.5 million, with a median of $4.7 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Current Assets sank 62.87% in 2022, then soared 392.84% in 2025.
• Over 5 years, Current Assets stood at $5.3 million in 2022, then slipped by 12.33% to $4.7 million in 2023, then slumped by 43.27% to $2.6 million in 2024, then soared by 392.84% to $13.0 million in 2025, then sank by 74.0% to $3.4 million in 2026.
• The last three Current Assets figures came in at $3.4 million (Q2 2026), $13.0 million (Q4 2025), and $3.7 million (Q3 2025), per Business Quant data.